Represents the Company’s 31st product launch since inception in October 2023
Broadens Avenacy’s injectable offerings supporting anesthesia and perioperative care.
SCHAUMBURG, Ill.–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Cisatracurium Besylate Injection, USP in the United States. Cisatracurium Besylate Injection, USP is a therapeutic generic equivalent to NIMBEX®, as approved by the U.S. Food and Drug Administration, and is indicated as an adjunct to general anesthesia to facilitate tracheal intubation, to provide skeletal muscle relaxation during surgery, and for mechanical ventilation in the intensive care unit in appropriate patient populations. Each vial of Cisatracurium Besylate Injection, USP contains 200 mg per 20 mL (10 mg/mL) and is available as a carton of 10 single-dose vials.
In line with Avenacy’s mission to champion patient safety and streamline patient care, Cisatracurium Besylate Injection, USP will feature the Company’s highly differentiated packaging and labeling to support accurate medication selection.
Avenacy will begin shipping Cisatracurium Besylate Injection, USP to wholesale partners this week. The Company is supported by a global network of development and contract manufacturing partners that have undergone successful FDA inspections based on cGMP standards.
Cisatracurium Besylate Injection, USP 10 mg/mL had U.S. sales of approximately $8.0 million for the twelve months ending in September 2026.¹
Indications and Contraindications
Cisatracurium Besylate Injection is a nondepolarizing neuromuscular blocker indicated as an adjunct to general anesthesia to facilitate tracheal intubation in adults and pediatric patients 1 month to 12 years of age; to provide skeletal muscle relaxation during surgery in adults and pediatric patients 2 to 12 years of age as a bolus or infusion maintenance; and for mechanical ventilation in the ICU in adults.
Limitations of Use: Cisatracurium Besylate Injection is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action.
Cisatracurium Besylate Injection is contraindicated in patients with known hypersensitivity to cisatracurium.
Please see link for Full Prescribing Information.
NIMBEX® is a registered trademark of GlaxoSmithKline.
¹Source: IQVIA
About Avenacy
Avenacy is a U.S.-based specialty pharmaceutical company focused on supplying critical injectable medications used to treat patients in various medically supervised settings, from acute care hospitals to outpatient clinics and physician offices. Through a rigorous and optimized selection process, the Company is building out a pipeline of high-quality FDA approved injectable products in order to ensure a resilient portfolio that can meet the needs of today’s dynamic drug supply chain. With an experienced team, commitment to quality and reliability, and product offerings intended to facilitate safe and efficient patient care, Avenacy strives to be a trusted partner for essential medications.
Avenacy was launched in 2023 and is headquartered in Schaumburg, IL. For more information, please visit https://www.avenacy.com.
Contacts
Media Contact
FTI Consulting
Avenacy@fticonsulting.com
